Primary sclerosing cholangitis is a chronic liver disease that may occur alone or be caused by other diseases.The disease is characterized by inflammation and thickening of the bile ducts.This impedes bile flow and may lead to other liver diseases.Primary sclerosing cholangitis (PSC) is treated in addition to PSC and avoids other liver diseases.Available options are liver transplantation, UDCA drugs, and PSC drugs, each with advantages and disadvantages in cost and efficacy.
This report contains market size and forecasts of Primary Sclerosing Cholangitis Treatment in Global, including the following market information:
Global Primary Sclerosing Cholangitis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Primary Sclerosing Cholangitis Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Liver Transplantation Operation Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Primary Sclerosing Cholangitis Treatment include Allergan, Glenmark, Impax Laboratories, Mylan, Teva Pharmaceuticals, Dr. Falk Pharma, Daewoong Pharmaceutical, Epic Pharma and Mitsubishi Tanabe Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Primary Sclerosing Cholangitis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Primary Sclerosing Cholangitis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Primary Sclerosing Cholangitis Treatment Market Segment Percentages, by Type, 2021 (%)
Liver Transplantation Operation
UDCA Drugs
PSC Drugs
Global Primary Sclerosing Cholangitis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Primary Sclerosing Cholangitis Treatment Market Segment Percentages, by Application, 2021 (%)
Hospital
Clinics
Other
Global Primary Sclerosing Cholangitis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Primary Sclerosing Cholangitis Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Primary Sclerosing Cholangitis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Primary Sclerosing Cholangitis Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan
Glenmark
Impax Laboratories
Mylan
Teva Pharmaceuticals
Dr. Falk Pharma
Daewoong Pharmaceutical
Epic Pharma
Mitsubishi Tanabe Pharma
Lannett
Bruschettini
Shanghai Pharma
Grindeks
Acorda Therapeutics
Gilead Sciences
Intercept Pharmaceuticals
Shire Plc
NGM Biopharmaceuticals
Conatus Pharmaceuticals
Durect Corporation
Sirnaomics
Shenzhen HighTide Biopharmaceuticals